Endonovo Therapeutics, Inc. Stock
Stocks
ENDV
US29272H3003
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | -.--% |
|
+9,900.00% | - |
| Market Cap | 2.77M 2.4M 2.24M 2.05M 3.87M 264M 3.93M 26.28M 10.32M 132M 10.41M 10.19M 437M | P/E 2021 |
-0.3x | P/E 2022 | -0.14x |
|---|---|---|---|---|---|
| Enterprise Value | 9.93M 8.59M 8.02M 7.36M 13.83M 945M 14.05M 94.07M 36.92M 474M 37.28M 36.46M 1.57B | EV / Sales 2021 |
112,421,804x | EV / Sales 2022 | 78,689,579x |
| Free-Float |
100% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 week | +9,900.00% | ||
| Current month | +9,900.00% |
| 1 week | 0 | 0 | |
| 1 month | 0 | 0 | |
| Current year | 0 | 0 | |
| 1 year | 0 | 0 | |
| 3 years | 0 | 0.02 | |
| 5 years | 0 | 0.06 | |
| 10 years | 0 | 200 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 61 | 2012-02-29 |
Steven Barnes
IRC | Investor Relations Contact | - | 2014-04-30 |
Ira Weisberg
PRN | Corporate Officer/Principal | 77 | 2022-11-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Alan Collier
CHM | Chairman | 61 | 2012-02-29 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/30/20 | Buy | Chief Executive Officer | 400 | 0.0045% | ||
| 2/21/20 | Buy | Chief Executive Officer | 100 | 0.0107% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | +9,900.00% | -.--% | -99.01% | 90.38K | ||
| +8.49% | +20.55% | +70.77% | +103.07% | 68.12B | ||
| -1.15% | +4.46% | +36.37% | +65.08% | 55.18B | ||
| -1.09% | +32.96% | +19.67% | +509.20% | 28.63B | ||
| +0.57% | +18.87% | +55.18% | +5.18% | 23.99B | ||
| +2.72% | +3.41% | -16.11% | -12.04% | 23.53B | ||
| -1.74% | +6.39% | +44.68% | -23.70% | 18.45B | ||
| -2.04% | +10.84% | +31.01% | +628.97% | 16.44B | ||
| -3.88% | +16.98% | +199.30% | +350.94% | 15.83B | ||
| +3.58% | +1.96% | +43.35% | +162.22% | 13.4B | ||
| Average | +0.55% | +10.51% | +48.42% | +168.99% | 26.36B | |
| Weighted average by Cap. | +1.83% | +13.10% | +50.86% | +161.86% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.96 0.1 0.69 0.27 3.49 0.27 0.27 11.53 | 0.14 0.12 0.11 0.1 0.19 12.88 0.19 1.28 0.5 6.46 0.51 0.5 21.35 |
| Net income | -3.1M -2.69M -2.51M -2.3M -4.33M -295M -4.4M -29.43M -11.55M -148M -11.66M -11.4M -490M | -18.47M -15.98M -14.92M -13.69M -25.75M -1.76B -26.16M -175M -68.72M -881M -69.38M -67.86M -2.91B |
| Net Debt | 7.1M 6.14M 5.73M 5.26M 9.89M 675M 10.05M 67.24M 26.39M 338M 26.64M 26.06M 1.12B | 7.15M 6.19M 5.78M 5.3M 9.97M 681M 10.13M 67.79M 26.61M 341M 26.86M 26.27M 1.13B |
Employees
1
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-07 | US$0.000050 | +4,900.00% | 1,399,999 |
| 26-08-06 | US$0.000001 | -99.00% | 12,001 |
| 26-08-03 | US$0.000100 | +9,900.00% | 999,999 |
- Stock Market
- Stocks
- ENDV Stock
Select your edition
All financial news and data tailored to specific country editions
















